174 related articles for article (PubMed ID: 27605068)
1. Specific immunotherapy in ovarian cancer: a systematic review.
Aalipour S; Zoghi S; Khalili N; Hirbod-Mobarakeh A; Emens LA; Rezaei N
Immunotherapy; 2016 Oct; 8(10):1193-204. PubMed ID: 27605068
[TBL] [Abstract][Full Text] [Related]
2. Antigen-specific active immunotherapy for ovarian cancer.
Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief CJ; Nijman HW
Cochrane Database Syst Rev; 2014 Sep; (9):CD007287. PubMed ID: 25229990
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy in epithelial ovarian carcinoma: hope and reality].
Lavoué V; Foucher F; Henno S; Bauville E; Catros V; Cabillic F; Levêque J
J Gynecol Obstet Biol Reprod (Paris); 2014 Mar; 43(3):198-210. PubMed ID: 24230482
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy opportunities in ovarian cancer.
Chu CS; Kim SH; June CH; Coukos G
Expert Rev Anticancer Ther; 2008 Feb; 8(2):243-57. PubMed ID: 18279065
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
Wang W; Zou W; Liu JR
Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508
[No Abstract] [Full Text] [Related]
6. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.
Joly F; Hilpert F; Okamoto A; Stuart G; Ochiai K; Friedlander M;
Eur J Cancer; 2017 Jun; 78():133-138. PubMed ID: 28448857
[TBL] [Abstract][Full Text] [Related]
7. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer.
Lavoué V; Thédrez A; Levêque J; Foucher F; Henno S; Jauffret V; Belaud-Rotureau MA; Catros V; Cabillic F
J Transl Med; 2013 Jun; 11():147. PubMed ID: 23763830
[TBL] [Abstract][Full Text] [Related]
8. A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.
Thedrez A; Lavoué V; Dessarthe B; Daniel P; Henno S; Jaffre I; Levêque J; Catros V; Cabillic F
PLoS One; 2013; 8(5):e63322. PubMed ID: 23717410
[TBL] [Abstract][Full Text] [Related]
9. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer.
Cândido EB; Silva LM; Carvalho AT; Lamaita RM; Filho RM; Cota BD; da Silva-Filho AL
Reprod Sci; 2013 Jul; 20(7):828-37. PubMed ID: 23239818
[TBL] [Abstract][Full Text] [Related]
10. Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine.
Wu D; Wang J; Cai Y; Ren M; Zhang Y; Shi F; Zhao F; He X; Pan M; Yan C; Dou J
J Ovarian Res; 2015 Oct; 8():68. PubMed ID: 26497895
[TBL] [Abstract][Full Text] [Related]
11. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
12. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
[TBL] [Abstract][Full Text] [Related]
13. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).
Oei AL; Sweep FC; Thomas CM; Boerman OC; Massuger LF
Int J Oncol; 2008 Jun; 32(6):1145-57. PubMed ID: 18497976
[TBL] [Abstract][Full Text] [Related]
14. Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
Heitz F; Hengsbach A; Harter P; Traut A; Ataseven B; Schneider S; Prader S; Kurzeder C; Sporkmann M; du Bois A
Gynecol Oncol; 2017 Jan; 144(1):181-186. PubMed ID: 27863705
[TBL] [Abstract][Full Text] [Related]
15. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
16. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
[TBL] [Abstract][Full Text] [Related]
17. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
Vermeij R; de Bock GH; Leffers N; Ten Hoor KA; Schulze U; Hollema H; van der Burg SH; van der Zee AG; Daemen T; Nijman HW
J Immunother; 2011; 34(6):516-23. PubMed ID: 21654520
[TBL] [Abstract][Full Text] [Related]
20. Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II.
Mazumder S; Johnson JM; Swank V; Dvorina N; Martelli E; Ko J; Tuohy VK
Cancer Prev Res (Phila); 2017 Nov; 10(11):612-624. PubMed ID: 29093011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]